Questions: Chronic Kidney Disease and Progressive Renal Failure

Question 1

A patient loses 50% of their nephrons acutely. Their total GFR initially falls but then partially recovers over several months, despite no nephron regeneration. What is the most likely explanation?

• A. Compensatory tubular hypertrophy allows surviving tubules to filter more plasma
• B. Remaining nephrons increase their individual filtration rates through hyperfiltration, driven by afferent arteriole dilation and elevated intraglomerular pressure
• C. Creatinine secretion increases to maintain apparent serum creatinine levels
• D. The juxtaglomerular apparatus upregulates renin to recruit reserve nephrons

Answer: (B)

The kidney cannot regenerate nephrons, but surviving nephrons adapt through hyperfiltration: afferent arteriolar dilation raises intraglomerular hydrostatic pressure, increasing single-nephron GFR. This partially compensates for total GFR loss in the short term. The tragic consequence is that elevated glomerular pressure physically stresses the capillary wall, promoting mesangial expansion and podocyte damage — initiating the self-amplifying cycle of proteinuria, tubular toxicity, and further nephron loss that characterizes CKD progression.

Question 2

A patient with stage 3 CKD has had a stable serum creatinine of 2.1 mg/dL for two years. Cystatin C-based eGFR measurements over the same period show a decline from 42 to 31 mL/min. Which explanation best accounts for this discordance?

• A. Cystatin C is an unreliable biomarker that fluctuates with diet and should not be used in isolation
• B. As GFR falls, remaining tubules increase creatinine secretion, maintaining serum creatinine lower than true filtration would predict
• C. Creatinine is freely filtered and never secreted, so it always accurately reflects GFR regardless of disease stage
• D. The patient's increased muscle mass has raised creatinine production to offset the GFR decline

Answer: (B)

Creatinine is both filtered and secreted by the proximal tubule. At normal GFR, secretion accounts for a modest fraction of creatinine excretion. As GFR falls, the secreted fraction increases — tubular secretion compensates for declining filtration, keeping serum creatinine artificially low relative to true GFR. Cystatin C is filtered but neither secreted nor reabsorbed, making it a cleaner GFR surrogate in CKD. The clinical danger is that a 'stable' creatinine can mask progressive nephron loss — the patient may be deteriorating significantly while the standard blood test appears reassuring.

Question 3

Hyperfiltration by surviving nephrons in CKD is simultaneously compensatory (helping maintain total GFR) and damaging (accelerating further nephron loss through glomerular hypertension).

• T. True
• F. False

Answer: True

This dual nature is the core of the hyperfiltration hypothesis and what makes CKD self-amplifying. Surviving nephrons dilate their afferent arterioles and increase intraglomerular pressure to partially restore total GFR. But the elevated mechanical stress on the glomerular capillary wall promotes mesangial expansion, podocyte injury, and proteinuria. Protein in the tubular filtrate is directly toxic to tubular cells, causing interstitial fibrosis and tubular atrophy — destroying additional nephrons and increasing the burden on those that remain, further elevating hyperfiltration. The compensation that buys time also drives the disease forward.

Question 4

Microalbuminuria in CKD is a benign finding that simply reflects reduced filtering capacity and does not independently predict the rate of disease progression.

• T. True
• F. False

Answer: False

Microalbuminuria is both a marker and a mediator of progressive kidney damage. As a marker, it reflects glomerular injury: albumin crosses the damaged filtration barrier in amounts that exceed the tubule's reabsorptive capacity, signaling ongoing glomerulosclerosis. As a mediator, albuminuria independently predicts the rate of GFR decline — higher proteinuria correlates with faster progression even after controlling for GFR. Protein reabsorbed by proximal tubular cells triggers inflammatory and fibrotic cascades in the interstitium. Reducing proteinuria through RAAS blockade, glycemic control, or SGLT2 inhibitors is itself a therapeutic target in CKD management.

Question 5

Explain the specific hemodynamic mechanism by which ACE inhibitors or ARBs slow CKD progression beyond simply lowering systemic blood pressure.

Model answer: RAAS blockade inhibits angiotensin II, which normally constricts the efferent arteriole (the vessel leaving the glomerulus). By dilating the efferent arteriole specifically, ACE inhibitors and ARBs lower intraglomerular hydrostatic pressure without proportionally reducing renal blood flow. In hyperfiltrating nephrons, it is efferent constriction driven by angiotensin II that maintains the elevated glomerular pressure causing mechanical stress on the capillary wall and driving proteinuria. By directly reducing this intraglomerular pressure, RAAS blockade interrupts the hyperfiltration-proteinuria-fibrosis cycle that drives CKD progression.

This efferent-specific mechanism explains why RAAS blockade provides renoprotection beyond what blood pressure reduction alone would predict — a finding established in landmark clinical trials in diabetic nephropathy. It also explains why ACE inhibitors and ARBs can cause acute kidney injury in bilateral renal artery stenosis: in that setting, afferent perfusion is already compromised, and losing efferent tone drops the filtration pressure needed to maintain GFR.